Develops novel cancer immunotherapies, focusing on engineering immune cells to target and destroy cancer cells.
CERo Therapeutics Holdings, Inc., specializes in pioneering immunotherapy treatments with a primary focus on advancing engineered T cell therapeutics to combat various forms of cancer.
At the forefront of its innovative pipeline is CER-1236, the company's leading candidate in the development of autologous T cell therapy designed specifically for treating hematologic malignancies. This promising therapeutic approach underscores CERo Therapeutics' commitment to leveraging cutting-edge biotechnologies to address critical medical challenges in oncology.
Founded in 2021 and headquartered in South San Francisco, California, CERo Therapeutics Holdings, Inc., continues to drive forward with its mission to transform cancer treatment paradigms through advanced immunotherapies, aiming to improve patient outcomes and pave the way for new standards in oncological care.